Mersana Therapeutics Net Worth 2016-2022 | MRSN
Interactive chart of historical net worth (market cap) for Mersana Therapeutics (MRSN) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Mersana Therapeutics net worth as of January 27, 2023 is $0.65B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.646B | $0.000B |
| Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $155.188B | 9.47 |
| GSK (GSK) | United Kingdom | $72.345B | 9.01 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.069B | 28.64 |
| QIAGEN (QGEN) | Netherlands | $11.333B | 19.34 |
| Ginkgo Bioworks Holdings (DNA) | United States | $3.395B | 0.00 |
| Myovant Sciences (MYOV) | United Kingdom | $2.604B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.672B | 25.10 |
| Biohaven (BHVN) | United States | $1.264B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.655B | 5.15 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.363B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.073B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.073B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.027B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.025B | 0.00 |
